Roche Tasmar Phase IIIb trial in early Parkinson's, first-time levodopa users under way.
ROCHE TASMAR PHASE IIIb EARLY PARKINSON's DISEASE STUDY is under way to look at tolcapone's ability to delay the onset of fluctuation (uncontrollable muscle movements) in patients receiving levodopa for the first time. In the six-year Delayed Onset of Fluctuation study, early Parkinson's disease patients are receiving tolcapone plus levodopa or levodopa alone.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth